Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
12.1(c) 12.15(c) 11.7(c) 11.85(c) 11.8(c) Last
345 208 442 655 752 873 383 397 424 970 Volume
-0.41% +0.41% -3.70% +1.28% -0.42% Change
More quotes
Financials ($)
Sales 2017 234 M
EBIT 2017 15,6 M
Net income 2017 -40,0 M
Debt 2017 243 M
Yield 2017 -
Sales 2018 245 M
EBIT 2018 92,2 M
Net income 2018 53,0 M
Debt 2018 138 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 15,53
EV / Sales2017 3,39x
EV / Sales2018 2,81x
Capitalization 549 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs.It focuses on gastroenterology, ophthalmology, and oncology-related disorders.The company's product pipeline includes AMITIZA for... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
09/22 SUCAMPO PHARMACEUTICALS ANNOUNCES WE : Rare Disease & Immuno-Oncology
09/21 CANCER PREVENTION PHARMACEUTICALS : Receives $9.5 Million in Additional Funding ..
09/21 SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 2017 Cant..
09/21 SUCAMPO PHARMACEUTICALS ANNOUNCES WE : Rare Disease & Immuno-Oncology
09/20 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Finan..
09/20 Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
09/19 SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 2017 Cant..
09/14 SUCAMPO PHARMACEUTICALS : Cancer Prevention Pharmaceuticals Receives $9.5 Millio..
09/11 SUCAMPO PHARMACEUTICALS : Cancer Prevention Pharmaceuticals Receives $9.5 Millio..
09/11 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Entry into a Material ..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
SUCAMPO PHARMACEUTICALS - 2015
The bullish trend is not over
BUY
More Strategies
Latest Tweets
09/21Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Lee.. 
09/21Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Lee.. 
09/21Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel  
09/20Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Can.. 
09/19Notable entries today, courtesy of Holly AI . Learn how AI can help your tra..
1
More tweets
Qtime:41
News from SeekingAlpha
09/11 Faison's Weekend Review And Scans
09/07 Sucampo Firing Sales Torpedos
08/21 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
08/21 Premarket analyst action - healthcare
08/02 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q2 2017 Results - Earn..
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 18,1 $
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Matthew Maxwell Donley EVP-Human Resources & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.-12.55%549
AMGEN27.65%135 544
CELGENE CORPORATION24.22%112 572
GILEAD SCIENCES15.37%108 744
REGENERON PHARMACEUTICALS18.08%46 367
VERTEX PHARMACEUTICALS106.41%38 136